These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37973190)

  • 1. Worldwide Regulatory Reliance: Launching a Pilot on a Chemistry, Manufacturing, and Control Post Approval Change for a Vaccine.
    Gastineau T; Ban C; Basso A; Brehme F; Silva AL; Faure O; Palaire LL; Persaud P; Rodriguez H
    PDA J Pharm Sci Technol; 2024 Aug; 78(4):388-398. PubMed ID: 37973190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unleashing the Power of Reliance for Post-Approval Changes: A Journey with 48 National Regulatory Authorities.
    Mangia F; Lin YM; Armando J; Dominguez K; Rozhnova V; Ausborn S
    Ther Innov Regul Sci; 2024 Nov; 58(6):997-1005. PubMed ID: 39048766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approaches to Design an Efficient, Predictable Global Post-approval Change Management System that Facilitates Continual Improvement and Drug Product Availability.
    Vinther A; Ramnarine E; Gastineau T; O'Brien L; Brehm O; Fryrear D
    Ther Innov Regul Sci; 2024 May; 58(3):433-442. PubMed ID: 38369639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Global Industry Survey on Post-Approval Change Management and Use of Reliance.
    Deavin A; Hossain A; Colmagne-Poulard I; Wong KC; Perea-Vélez M; Cappellini S; Ausborn S; Meillerais S; Bourguignon C
    Ther Innov Regul Sci; 2024 Nov; 58(6):1094-1107. PubMed ID: 39179719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alignment in post-approval changes (PAC) guidelines in emerging countries may increase timely access to vaccines: An illustrative assessment by manufacturers.
    Dellepiane N; Pagliusi S; Akut P; Comellas S; De Clercq N; Ghadge S; Gastineau T; McGoldrick M; Nurnaeni I; Scheppler L;
    Vaccine X; 2020 Dec; 6():100075. PubMed ID: 32995745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Path Forward to Optimise Post-approval Change Management and Facilitate Continuous Supply of Medicines and Vaccines of High Quality Worldwide : Joint Position from EFPIA, IFPMA and Vaccines Europe.
    Deavin A; Adam S; Ausborn S; Nielsen ASB; Cappellini S; Colmagne-Poulard I; Gastineau T; Gonzalez-Martinez A; Meillerais S; Mortazavi C
    Ther Innov Regul Sci; 2023 Jan; 57(1):7-11. PubMed ID: 35917091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to accelerate the supply of vaccines to all populations worldwide? Part I: Initial industry lessons learned and practical overarching proposals leveraging the COVID-19 situation.
    McGoldrick M; Gastineau T; Wilkinson D; Campa C; Clercq N; Mallia-Milanes A; Germay O; Krishnan J; Van Ooij M; Thien MP; Mlynarczyk PJ; Saltus E; Juvin P; Clenet D; Basso A; Dellepiane N; Pagliusi S; de Moraes Stávale MC; Sivaramakrishnan VH; Desai S
    Vaccine; 2022 Feb; 40(9):1215-1222. PubMed ID: 35180993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliance: a smarter way of regulating medical products - The IPRP survey.
    Doerr P; Valentin M; Nakashima N; Orphanos N; Santos G; Balkamos G; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2021 Feb; 14(2):173-177. PubMed ID: 33355025
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemistry Manufacturing and Controls Development, Industry Reflections on Manufacture, and Supply of Pandemic Therapies and Vaccines.
    Popkin ME; Goese M; Wilkinson D; Finnie S; Flanagan T; Campa C; Clinch A; Teasdale A; Lennard A; Cook G; Mohan G; Osborne MD
    AAPS J; 2022 Sep; 24(6):101. PubMed ID: 36168002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO collaborative registration procedure using stringent regulatory authorities' medicine evaluation: reliance in action?
    Vaz A; Roldão Santos M; Gwaza L; Mezquita González E; Pajewska Lewandowska M; Azatyan S; Saint-Raymond A
    Expert Rev Clin Pharmacol; 2022 Jan; 15(1):11-17. PubMed ID: 35130803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry One-Voice-of-Quality Solutions Management Review of Post-Approval Changes Guide.
    Vinther A; Mohammed F; Ramnarine E
    PDA J Pharm Sci Technol; 2021; 75(5):454-457. PubMed ID: 33723006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the impact of reliance on the regulatory performance in the South African Health Products Regulatory Authority: implications for African regulatory authorities.
    Danks L; Semete-Makokotlela B; Otwombe K; Parag Y; Walker S; Salek S
    Front Med (Lausanne); 2023; 10():1265058. PubMed ID: 37937144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the review models and approval timelines of authorities participating in the East African Medicine Regulatory Harmonisation initiative: alignment and strategies for moving forward.
    Ngum N; Ndomondo-Sigonda M; Habonimana R; Siyoi F; Irasabwa C; Ojukwu J; Apolinary F; Okello A; Ahmada S; Walker S; Salek S
    Front Med (Lausanne); 2024; 11():1438041. PubMed ID: 39355848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medicinal Product Development and Regulatory Agilities Implemented During the Early Phases of the COVID-19 Pandemic: Experiences and Implications for the Future-An Industry View.
    Geraci G; Bernat J; Rodier C; Acha V; Acquah J; Beakes-Read G
    Ther Innov Regul Sci; 2023 Sep; 57(5):940-951. PubMed ID: 37266868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solving the Global Continual Improvement and Innovation Challenge: How an Effective Pharmaceutical Quality System Can Transform Post-Approval Change Management.
    Vinther A; Ramnarine E
    PDA J Pharm Sci Technol; 2019; 73(5):517-521. PubMed ID: 31420505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
    Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
    PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for the chemistry, manufacturing and Controls (CMC) - quality package for COVID-19 vaccines- interim lessons learnt by the European medicines Agency (EMA).
    Shivji R; Conocchia R; Korakianiti E; Jekerle V
    Vaccine; 2022 Sep; 40(38):5539-5541. PubMed ID: 35779964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Proposal of a Combined Convergence Regulatory Strategy Applied to Post-approval Changes by Latin American Countries, Reducing Workload and Allowing Continuous Improvement to Guarantee the Quality, Safety, and Efficacy of Medicines.
    Rodriguez H; De Lucia ML
    Front Med (Lausanne); 2021; 8():768376. PubMed ID: 34888329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Harmonization and Streamlining of Clinical Trial Applications globally should lead to faster clinical development and earlier access to life-saving vaccines.
    Scheppler L; De Clercq N; McGoldrick M; Dias J
    Vaccine; 2021 Jan; 39(5):790-796. PubMed ID: 33422378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.